News AbbVie’s 8-week hepatitis C drug granted early access in UK AbbVie’s hepatitis C drug granted early access in UK
News AbbVie takes aim at Gilead and BMS with 8-week hep C treatme... Trial backs patient-friendly regime in tough to treat strain.
News Doubts over AbbVie PARP inhibitor after double trial failure Veliparib fails in two phase 3 trials.
News AbbVie’s elagolix shows promise in uterine fibroids treatmen... AbbVie's elagolix has shown promise in a phase 2 trial in women with uterine fibroids, a second indication for the pipeline drug, which could become a major earner for the company.
News UK court overturns AbbVie Humira patents Decision paves way for cheaper competitor in autumn 2018.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
